Literature DB >> 23587598

Adenylyl cyclase 6 deletion increases mortality during sustained β-adrenergic receptor stimulation.

Tong Tang1, N Chin Lai, Adam T Wright, Mei Hua Gao, Paul Lee, Tracy Guo, Ruoying Tang, Andrew D McCulloch, H Kirk Hammond.   

Abstract

Sustained β-adrenergic receptor stimulation is associated with cardiomyopathy, an affect thought to result from cAMP-associated cardiac injury. Using a murine line with adenylyl cyclase 6 gene deletion (AC6KO), we tested the hypothesis that AC6 deletion, by limiting cAMP production, would attenuate cardiomyopathy in the setting of sustained β-adrenergic receptor stimulation. During 7d isoproterenol infusion, there was unexpected higher mortality in AC6KO mice compared to wild type control mice (p<0.0001). However, left ventricular function was similarly impaired in isoproterenol-infused control and AC6KO mice. There were no group differences in left ventricular hypertrophy, apoptosis, and fibrosis. Telemetric electrocardiography showed progressive prolongation of PR interval (p<0.0001), QRS duration (p<0.0005), and QTc (p<0.0001), as well as reduction in heart rate (p<0.0001), in AC6KO mice during isoproterenol infusion. These defective electrophysiological properties in isoproterenol-infused AC6KO mice were associated with decreased longitudinal ventricular conduction velocity (p<0.05) and reduced phosphorylation of connexin 43 at S368 in left ventricular samples (p=0.006). Taken together, these data demonstrate that limiting cAMP production does not prevent sustained β-adrenergic receptor stimulation-induced cardiomyopathy. Moreover, AC6 deletion impairs electrophysiological properties and increases mortality during sustained β-adrenergic receptor stimulation. Decreased connexin 43 phosphorylation and impaired ventricular conduction may be of mechanistic importance for the defective electrophysiological properties.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23587598      PMCID: PMC3987812          DOI: 10.1016/j.yjmcc.2013.04.005

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  36 in total

1.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2011-12-15       Impact factor: 29.690

Review 2.  Arrhythmogenic implications of fibroblast-myocyte interactions.

Authors:  Stephan Rohr
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-04

Review 3.  Animal models of heart failure: a scientific statement from the American Heart Association.

Authors:  Steven R Houser; Kenneth B Margulies; Anne M Murphy; Francis G Spinale; Gary S Francis; Sumanth D Prabhu; Howard A Rockman; David A Kass; Jeffery D Molkentin; Mark A Sussman; Walter J Koch; Walter Koch
Journal:  Circ Res       Date:  2012-05-17       Impact factor: 17.367

4.  Adenylyl cyclase 6 deletion reduces left ventricular hypertrophy, dilation, dysfunction, and fibrosis in pressure-overloaded female mice.

Authors:  Tong Tang; N Chin Lai; H Kirk Hammond; David M Roth; Yuan Yang; Tracy Guo; Mei Hua Gao
Journal:  J Am Coll Cardiol       Date:  2010-04-06       Impact factor: 24.094

5.  Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice.

Authors:  J D Bisognano; H D Weinberger; T J Bohlmeyer; A Pende; M V Raynolds; A Sastravaha; R Roden; K Asano; B C Blaxall; S C Wu; C Communal; K Singh; W Colucci; M R Bristow; D J Port
Journal:  J Mol Cell Cardiol       Date:  2000-05       Impact factor: 5.000

6.  Conduction remodeling in human end-stage nonischemic left ventricular cardiomyopathy.

Authors:  Alexey V Glukhov; Vadim V Fedorov; Paul W Kalish; Vinod K Ravikumar; Qing Lou; Deborah Janks; Richard B Schuessler; Nader Moazami; Igor R Efimov
Journal:  Circulation       Date:  2012-03-12       Impact factor: 29.690

7.  Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level.

Authors:  S B Liggett; N M Tepe; J N Lorenz; A M Canning; T D Jantz; S Mitarai; A Yatani; G W Dorn
Journal:  Circulation       Date:  2000-04-11       Impact factor: 29.690

8.  Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43.

Authors:  D E Gutstein; G E Morley; H Tamaddon; D Vaidya; M D Schneider; J Chen; K R Chien; H Stuhlmann; G I Fishman
Journal:  Circ Res       Date:  2001-02-16       Impact factor: 17.367

9.  Phosphatase-resistant gap junctions inhibit pathological remodeling and prevent arrhythmias.

Authors:  Benjamin F Remo; Jiaxiang Qu; Frank M Volpicelli; Steven Giovannone; Daniel Shin; Joshua Lader; Fang-Yu Liu; Jie Zhang; Danielle S Lent; Gregory E Morley; Glenn I Fishman
Journal:  Circ Res       Date:  2011-04-28       Impact factor: 17.367

Review 10.  Tackling heart failure in the twenty-first century.

Authors:  James O Mudd; David A Kass
Journal:  Nature       Date:  2008-02-21       Impact factor: 49.962

View more
  18 in total

1.  Conduction in the right and left ventricle is differentially regulated by protein kinases and phosphatases: implications for arrhythmogenesis.

Authors:  Alexey V Zaitsev; Natalia S Torres; Keiko M Cawley; Amira D Sabry; Junco S Warren; Mark Warren
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-03-15       Impact factor: 4.733

2.  Sodium/calcium exchanger is upregulated by sulfide signaling, forms complex with the β1 and β3 but not β2 adrenergic receptors, and induces apoptosis.

Authors:  Jana Markova; Sona Hudecova; Andrea Soltysova; Marta Sirova; Lucia Csaderova; Lubomira Lencesova; Karol Ondrias; Olga Krizanova
Journal:  Pflugers Arch       Date:  2013-10-10       Impact factor: 3.657

3.  Kvβ1.1 (AKR6A8) senses pyridine nucleotide changes in the mouse heart and modulates cardiac electrical activity.

Authors:  Jared Tur; Kalyan C Chapalamadugu; Christopher Katnik; Javier Cuevas; Aruni Bhatnagar; Srinivas M Tipparaju
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-12-16       Impact factor: 4.733

4.  Response to Letter to the Editor on "Does Vidarabine Mediate Cardioprotection via Inhibition of AC5?".

Authors:  Claudio A Bravo; Dorothy E Vatner; Stephen F Vatner
Journal:  J Pharmacol Exp Ther       Date:  2016-08       Impact factor: 4.030

5.  Isoform selectivity of adenylyl cyclase inhibitors: characterization of known and novel compounds.

Authors:  Cameron S Brand; Harrison J Hocker; Alemayehu A Gorfe; Claudio N Cavasotto; Carmen W Dessauer
Journal:  J Pharmacol Exp Ther       Date:  2013-09-04       Impact factor: 4.030

Review 6.  International Union of Basic and Clinical Pharmacology. CI. Structures and Small Molecule Modulators of Mammalian Adenylyl Cyclases.

Authors:  Carmen W Dessauer; Val J Watts; Rennolds S Ostrom; Marco Conti; Stefan Dove; Roland Seifert
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

7.  Vidarabine, an anti-herpesvirus agent, prevents catecholamine-induced arrhythmias without adverse effect on heart function in mice.

Authors:  Kenji Suita; Takayuki Fujita; Wenqian Cai; Yuko Hidaka; Huiling Jin; Rajesh Prajapati; Masanari Umemura; Utako Yokoyama; Motohiko Sato; Björn C Knollmann; Satoshi Okumura; Yoshihiro Ishikawa
Journal:  Pflugers Arch       Date:  2018-02-16       Impact factor: 3.657

8.  Cardiac Adenylyl Cyclase and Phosphodiesterase Expression Profiles Vary by Age, Disease, and Chronic Phosphodiesterase Inhibitor Treatment.

Authors:  Stephanie J Nakano; Juliana Sucharov; Robert van Dusen; Mackenzie Cecil; Karin Nunley; Sean Wickers; Anis Karimpur-Fard; Brian L Stauffer; Shelley D Miyamoto; Carmen C Sucharov
Journal:  J Card Fail       Date:  2016-07-15       Impact factor: 5.712

Review 9.  Pathological cardiac hypertrophy: the synergy of adenylyl cyclases inhibition in cardiac and immune cells during chronic catecholamine stress.

Authors:  Gabriel Komla Adzika; Jeremiah Ong'achwa Machuki; Wenkang Shang; Hongjian Hou; Tongtong Ma; Lijuan Wu; Juan Geng; Xide Hu; Xianluo Ma; Hong Sun
Journal:  J Mol Med (Berl)       Date:  2019-05-06       Impact factor: 4.599

Review 10.  cAMP signaling in subcellular compartments.

Authors:  Konstantinos Lefkimmiatis; Manuela Zaccolo
Journal:  Pharmacol Ther       Date:  2014-04-01       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.